SS Innovations Submitted FDA Response for SSi Mantra
The company provided final clinical and validation data to the FDA to support the 510(k) submission for its surgical system.
Updated on Oct. 13, 2026 in Robotics
Live Poll
Do you believe new robotic surgery technologies offer significant benefits for patients in your area?
SS Innovations submitted a formal response to the FDA regarding the 510(k) filing for its SSi Mantra robotic surgical system. The submission includes final results from human clinical and validation studies.
Why it matters
The submission aims to demonstrate that the SSi Mantra system fulfills all regulatory requirements for safety, efficacy, and clinical feasibility. Achieving this clearance is a critical milestone for the company to bring its technology to market.
The SSi Mantra system has been validated across 190 different surgical procedures. The company provided final data from an expanded human clinical and human factors validation study to support the regulatory request.
The players
SS Innovations
This medical technology company specializes in the development of robotic surgical systems and related healthcare innovations.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.
Daniel & Daniel Consulting, LLC
This firm provides professional consulting services and assistance with regulatory submission materials for medical device manufacturers.
The details
The response includes results from a bridging study conducted in August 2026 at the Hospital Internacional de Colombia in Bucaramanga. Daniel & Daniel Consulting, LLC assisted the company in preparing the final materials for the submission, which specifically covers cholecystectomy procedures.
Timeline
August 2026: The bridging study was completed in Bucaramanga, Colombia.
October 5, 2026: SS Innovations submitted its response to the FDA.
Q1 2027: The FDA is expected to complete its review of the submission.
The Tech Race
The development of robotic surgical platforms reflects a broader industry shift toward increased automation in complex medical procedures. This move positions the SSi Mantra against established competitors in the robotic surgery space by seeking formal regulatory validation for its capabilities.
A successful regulatory review could eventually provide hospitals with more options for minimally invasive surgical equipment. This could lead to broader accessibility for surgeons to utilize robotic systems during routine cholecystectomy procedures.
The takeaway
Companies in the surgical robotics sector must provide extensive clinical and human factors data to meet rigorous federal safety standards. Future regulatory outcomes for new devices like the SSi Mantra depend on the successful completion of these multi-phase validation studies.
Further reading
For more information on the evolving landscape of medical automation, visit the Robotics section.
Live Poll
Do you believe new robotic surgery technologies offer significant benefits for patients in your area?
